Project Grant HT94252310467

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $457,683 to the Beckman Research Institute of the City of Hope to develop and evaluate novel "Bio-Beacons" - tumor-targeting bacterial vectors engineered to secrete chemokines and cytokines. The goal is to increase the density of tumor-reactive immune cells, such as CD8 T cells, CD4 T cells, dendritic cells, and natural killer cells, within solid tumors. This is...

The National Cancer Institute (NCI), under the federal Cancer Biology Research grant program (CFDA 93.396), awarded a $218,089 Project Grant to the University of California, Santa Barbara (UCSB) to develop and evaluate a novel chimeric antigen receptor macrophage (CAR-M) immunotherapy for the treatment of triple-negative breast cancer (TNBC). The project, titled "RAC-Enhanced Chimeric Antigen Receptor-Macrophage (RACE-CAR-M) Immunotherapy for Triple Negative Breast Cancer," aims to...

The National Science Foundation (NSF) awarded a $353,843 Project Grant under the NSF Engineering program (CFDA 47.041) to the University of Washington for the development of "Programmable and Dynamically-Responsive Bacterial Therapeutics for Cancer Immunotherapy". The project aims to create a novel biosensing system in E. coli bacteria to detect specific tumor antigens and respond with potent therapeutic payloads. In parallel, the research will engineer bacteria with improved tumor...

This Project Grant award from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Targeting Systems to develop a novel intramuscular gene delivery platform capable of sustained expression and endogenous secretion of bispecific natural killer cell engager (BIKE) therapeutics to treat solid tumors like hepatocellular carcinoma. The platform aims to deliver BIKEs in a less invasive manner than current immunotherapies,...

This federal Project Grant award of $399,829, awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports research to validate the use of positron emission tomography (PET) imaging to quantitatively measure the levels of the sphingosine-1-phosphate receptor 1 (S1PR1) in gastric tumors. The goal is to use this S1PR1-targeted PET imaging approach to predict and monitor the response of gastric tumors to antibody-drug conjugate...

Federal Grant Award Summary Endure Biotherapeutics, Inc. received a $392,827 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to develop engineered native bacteria (ENB) as a novel therapeutic approach for familial adenomatous polyposis (FAP). The award, effective August 5, 2025, with completion targeted for July 31, 2026, supports the advancement of the company's platform technology that engineers native gut bacteria to express...

This Project Grant award, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), will fund a pilot study to evaluate the associations of pre- and post-chemotherapy and -radiotherapy gut microbiome profiles with breast cancer recurrence and mortality. The $175,000 award will support the use of shotgun metagenome sequencing on 110 post-treatment stool samples from the Vietnam Breast Cancer Study, as well as an investigation of the impact of...

The U.S. Defense Health Agency awarded a $907,170 Project Grant to the Provincial Health Services Authority (operating as BC Cancer) in Canada. This grant, provided under the Department of Defense's Military Medical Research and Development program (CFDA 12.420), supports research on therapeutic targeting of genomic instability in triple-negative breast cancer. The 3-year project, running from September 2023 to September 2026, aims to advance the understanding and treatment of this aggressive...

This $871,016 Project Grant awarded on January 1, 2024 by the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) to the Beckman Research Institute of the City of Hope supports research on a highly tumor-specific oncolytic virus combined with a viral protein-target T cell engager for the treatment of triple-negative breast cancer. The grant aims to develop innovative therapies for this aggressive form of breast cancer that impacts military personnel and veterans. As a...

Summary Columbia University's Health Sciences Division received a $727,904 Cooperative Agreement award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) on August 11, 2025, for research on engineered probiotic bacteria to prevent and intercept colorectal cancer (CRC). The award supports a two-phase UG3/UH3 project designed to develop and characterize engineered strains of Escherichia coli Nissle 1917 (ECN) that selectively colonize precancerous lesions...